The basics:

• Merck aims to cut $3B in costs by end of 2027
• Job reductions planned across admin, sales and R&D
• Company to shrink global real estate and manufacturing
• Savings to support biotech, R&D and Keytruda expansion

Along with its financial results for the second quarter of 2025, Merck revealed plans designed to save $3 billion by the end of 2027.

According to the July 29 announcement, the company will fully reinvest anticipated gains from the multiyear optimization into strategic growth areas. As part of those moves, Merck said it expects to also cut jobs as part of the newly approved restructuring program.

Despite eliminating certain administrative, sales and R&D positions, the Rahway-based pharmaceutical giant also said it will continue to hire for new roles across the business’s strategic growth areas.

Merck also plans to shrink its footprint. The company said it will reduce its global real estate portfolio as it continues to optimize its manufacturing network. The moves aim to align global manufacturing sites with customers, reflecting changes in business, Merck said.

The company said it anticipates the restructuring program to result in annual cost savings of approximately $1.7 billion.

Merck representatives did not immediately respond to a request for comment regarding potential local impacts.

Future proofing

In Q2, the company noted it continued to make long-term investments in domestic R&D and manufacturing capabilities.

In April, Merck broke ground on a $1 billion biotechnology center in Delaware. That developing site will serve as a launch and commercial production facility as well as the primary U.S. manufacturing site for the company’s blockbuster cancer treatment, Keytruda (which posted 9% year-over-year growth during the quarter). Another $875 million expansion in Kansas will support Merck Animal Health manufacturing.

For the second quarter of 2025, the company recorded charges in its GAAP results of $649 million related to this restructuring program.

Total worldwide sales came in at $15.8 billion, a year-over-year decrease of 2%.

When it comes to pipeline, Merck’s Q2 assessment said the company continues to advance a broad and diverse one, having achieved multiple regulatory and clinical milestones.

Earlier this month, the company announced its planned $10 billion acquisition of Verona Pharma plc to expand its pipeline and portfolio of cardio-pulmonary treatments. Merck’s full-year 2025 outlook does not include that deal’s potential impact.

After referencing that acquisition, Merck Chairman and CEO Robert Davis shared thoughts on the $3 billion savings effort.

“Today, we announced a multiyear optimization initiative that will redirect investment and resources from more mature areas of our business to our burgeoning array of new growth drivers, further enable the transformation of our portfolio, and drive our next chapter of productive, innovation-driven growth,” he said. “With these actions, I am confident that we are well positioned to generate near- and long-term value for our shareholders and, most importantly, deliver for our patients.”

Analysts noted a drop in Merck stock following the optimization announcement, along with a 55% drop in Gardasil sales.